Li Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Qin has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Carlo Piermarocchi
Department of Physics and Astronomy Michigan State University East Lansing MI USA
1 shared publication- Fan Pan
Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology (SUAT), Shenzhen, PR China
1 shared publication - Giovanni Paternostro
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA
1 shared publication Hong Xin
Department of Pathology University of California San Diego La Jolla CA USA
1 shared publicationHui Ding
Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510632, P.R. China
1 shared publicationLixian Liu
Department of Pathology University of California San Diego La Jolla CA USA
1 shared publication
Latest Publications
- Open Access
- 15 November 2021
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (1) , e14511
LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy
In the course of our studies aiming to discover vascular bed‐specific endothelial cell (EC) mitogens, we identified leukemia inhibitory factor (LIF) as a mitogen for bovine choroidal EC (BCE), although LIF has been mainly characterized as an EC growth inhibitor and an anti‐angiogenic molecule. LIF stimulated growth of BCE while it inhibited, as previously reported, bovine aortic EC (BAE) growth. The JAK‐STAT3 pathway mediated LIF actions in both BCE and BAE cells, but a caspase‐independent proapoptotic signal mediated by cathepsins was triggered in BAE but not in BCE. LIF administration directly promoted activation of STAT3 and increased blood vessel density in mouse eyes. LIF also had protective effects on the choriocapillaris in a model of oxidative retinal injury. Analysis of available single‐cell transcriptomic datasets shows strong expression of the specific LIF receptor in mouse and human choroidal EC. Our data suggest that LIF administration may be an innovative approach to prevent atrophy associated with AMD, through protection of the choriocapillaris.
- 15 November 2021
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (1) , e14511
Open AccessLIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy
In the course of our studies aiming to discover vascular bed‐specific endothelial cell (EC) mitogens, we identified leukemia inhibitory factor (LIF) as a mitogen for bovine choroidal EC (BCE), although LIF has been mainly characterized as an EC growth inhibitor and an anti‐angiogenic molecule. LIF stimulated growth of BCE while it inhibited, as previously reported, bovine aortic EC (BAE) growth. The JAK‐STAT3 pathway mediated LIF actions in both BCE and BAE cells, but a caspase‐independent proapoptotic signal mediated by cathepsins was triggered in BAE but not in BCE. LIF administration directly promoted activation of STAT3 and increased blood vessel density in mouse eyes. LIF also had protective effects on the choriocapillaris in a model of oxidative retinal injury. Analysis of available single‐cell transcriptomic datasets shows strong expression of the specific LIF receptor in mouse and human choroidal EC. Our data suggest that LIF administration may be an innovative approach to prevent atrophy associated with AMD, through protection of the choriocapillaris.
- Open Access
- 20 June 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (3) , 3083-3091
Anterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti‑angiogenic treatment
Anti‑angiogenic therapy provides transient tumor vascular normalization, which results in a window of opportunity for improvement of radio‑ or chemotherapy. Biomarkers indicating this window are required for rationalizing anti‑angiogenesis. Anterior gradient 2 (AGR2), the majority of which is secreted from tumor cells, is an easily detected plasma protein. In the present study, it was demonstrated that AGR2 could be applied as a biomarker for the supervision of vascular normalization during anti‑angiogenic treatment with gold nanoparticles (AuNPs). Nude mice inoculated with SW620 human colorectal cancer cells were treated with AuNPs. Vessel density, pericyte coverage, vessel permeability, tumor hypoxia, tumor growth and AGR2 secretion were detected following treatment with AuNPs at days 0, 4, 6, 9 and 14. Tumor volume and vessel density were reduced, whereas pericyte coverage was increased, and hypoxia and vessel permeability were improved between days 6‑9; however, these improvements decreased by day 14, revealing a time frame for tumor vascular normalization, namely days 4‑9, during treatment with AuNPs in mice. AGR2 levels in tumor tissues and plasma were significantly low at day 9, along with vascular normalization; therefore, AGR2 can be used as a potential marker for monitoring tumor vascular normalization during anti‑angiogenic treatment.
- 20 June 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (3) , 3083-3091
Open AccessAnterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti‑angiogenic treatment
Anti‑angiogenic therapy provides transient tumor vascular normalization, which results in a window of opportunity for improvement of radio‑ or chemotherapy. Biomarkers indicating this window are required for rationalizing anti‑angiogenesis. Anterior gradient 2 (AGR2), the majority of which is secreted from tumor cells, is an easily detected plasma protein. In the present study, it was demonstrated that AGR2 could be applied as a biomarker for the supervision of vascular normalization during anti‑angiogenic treatment with gold nanoparticles (AuNPs). Nude mice inoculated with SW620 human colorectal cancer cells were treated with AuNPs. Vessel density, pericyte coverage, vessel permeability, tumor hypoxia, tumor growth and AGR2 secretion were detected following treatment with AuNPs at days 0, 4, 6, 9 and 14. Tumor volume and vessel density were reduced, whereas pericyte coverage was increased, and hypoxia and vessel permeability were improved between days 6‑9; however, these improvements decreased by day 14, revealing a time frame for tumor vascular normalization, namely days 4‑9, during treatment with AuNPs in mice. AGR2 levels in tumor tissues and plasma were significantly low at day 9, along with vascular normalization; therefore, AGR2 can be used as a potential marker for monitoring tumor vascular normalization during anti‑angiogenic treatment.